Theracryf PLC Share Chat (TCF)

Investor Meet Company

24 views 10 hours ago

https://youtu.be/gISs8GtUlpo?si=4GToF4p3kWkgXxda

Wile looking at RRR saw this is First Equity Limited largest holding at 4.68%

Also Rathbones Investment Management Limited 6%

And about eight other Investment Advisor/Hedge Funds

Yeah, they always sound reassuring. And I am sure it is splendid to be involved in this line of work as a scientist.

Interesting research and lab work, genuinely.

As for the warm words in these webinars....well, the share price (and the expanding number of shares in issue) tells an alternative story IMO. Hey ho. GLA.

Imagine taking any bonus whatsoever, when you have presided over a destruction in shareholder value like this.

More front than Blackpool, but so typically AIM.

Bio

We must have been on different webinars! They made it quite clear why they couldn't/didn't raise more on the recent fundraise

A significant part of research funding is being provided through 3rd party non-dilutive funding through multiple grants awarded to their research partners. Much of this is being provided from a governmental level. These surely are strong endorsements of the potential for TCF's developmental work?

I , for one, am a lot happier.

Doesn't Huw Jones remind you of Mr Bates?!!!

Not too shabby an investor presentation imo

Management took a bonus cut. Suspect this was due to small fundraise of 900K ..... odd that they couldn't raise more.

Cash runway looks OK to pay management, but NOT for R&D needed to create value.......

If there is an opportunity today I'll be submitting this question:

Can the board comment and provide investors with more information about the Stalicla findings published on the 8th May in MDPI "Characterization of a Clinically and Biologically Defined Subgroup of Patients with Autism Spectrum Disorder and Identification of a Tailored Combination Treatment" ?

The use of Sulforaphane purchased from MedChemExpress without reference to SFX-01 ?

Why did the board not consider this publication by it's partner worthy of an RNS ?

Let’s hope someone has asked the question for the board to answer this afternoon. If they don’t answer it today it could be a long time before any further updates.

Does anyone remember those adverts: 'If Carlsberg did....'?

Not sure why it came to mind :) GLA.

Stalicla deal gets sorted and all is good ;-)

I agree with you investor, I hadn’t factored in the share placing money raised, I think they have enough money to make it to 31/03/2025 but only just.

They really should update shareholders on what is going on with Stalicla now. It’s almost 4 months, do the shareholders or prospective investors not deserve to know?

Read the 'going concern' section. The Bod cannot make statements they believe are false. As outlined below, without the cash from the raise, they believe cash will last till Q4 25. The company have a decent runway when compared with peers.

"The Directors estimate that the cash held by the Group together with known receivables will be sufficient to support the current level of activities into the fourth quarter of 2025. They have therefore prepared the financial statements on a going concern basis."

Ok, fair point. They do appear to be funded for the rest of this year at least.

And the shares were issued at 1.44p/share, a premium of circa 50% at the time of issue.

No, Chronos investors were issued shares in TCF that cannot be sold for 18 months. The cash raised was in addition, to extend the cash runway of the company.

Investor - I thought the money raised in the share placing paid for the acquisition? They did have to pay money for the acquisition?

CJ,

While a resolution to the Stalicla saga would have been great, it was not likely for it to have been mentioned in the final year report, this will be a separate RNS. However, the report did go into more detail regarding this issue, under the 'OUTLICENSING' subsection although there was no new news here, as expected. The lack of mention of the $5.5m is disappointing.

However, Stalicla mentioned on the 8th May that they still anticipated STP 1 & 2 going into Phase 2 this year. "STP1 and STP2, both planned to enter Phase 2 trials in 2024." This, to me, shows that they are still going to progress SXF-01, and for Phase 2 trials to go ahead, IND needs to be approved by the FDA, so Stalicla will be legally obligated to pay TCF.

With regards to the cash burn, there are several issues with your analysis.

1. You have not included the £900k raised in early April.

2. You have assumed the cash burn will remain the same as previous years, which included reformulation of SFX-01 tablets.

3. The Bod themselves have said that they expect the cash to last into 2026, and continue to believe this is the case.

My first ever purchase here was at a price higher than that! Education on the AIM does not come cheap :)

The update simply underpins/adds evidence to my last few comments here really.

Going to watch the presentation at some point to get my fix of gallows humour.

Needless to say, I will not be adding here. But to each their own. GLA.

The thought is that they acquired this new company because they ran out of work with SFX-01. TCF do not have the money to do any of their own trials and they’ve been unable to get anyone to take SFX-01 on to trial it themselves. Where is the money going to come from to bankroll this company in a few months time. Such a poor update on the Stalicla situation, no mention at all now of $5.5m to be received this year.

If they hadn't raised £ to acquire another company you might be tempted to say game over. But raising and acquiring just doesn't sound like game over territory. That doesn't sound like a company on the path to delisting. Anyway not much I can say as I really don't know this company or its pipeline but its been on my must research/look at list - and I'd better go and do that research.

The highlights and outlook read really bad. Just a one line update on the Stalicla situation, they have totally removed the guidance of $5.5m expected in the next 12 months. No signs of any money incoming. Only £2m cash reserves as at end of March with a £250k a month cash burn. By those figures money will run out in November. No new updates on anything.

I think it’s game over here.

Just been looking over the share price history of EVG/TCF. On 28/05/2019, 5 years ago tomorrow the share price was 19.75p a share. If you bought £10,000 of shares 5 years ago your shares would now be worth £379. Brutal.

Although I sold out on Friday I am very interested to read tomorrow’s results, we will finally get an update on the Stalicla situation, almost 4 months since the dispute was issued. We will get to see what the current cash reserves look like and read about the outlook. I find it hard to believe that the results can be positive after the disastrous last twelve months. One year ago the share price was 3.95p, today it’s 0.75p, who really believed that would happen? I got told I was talking nonsense last summer for saying there would be a share placing at 1p in the Spring unless Stalicla money arrives, it happened.

If you had bought £10k worth of shares a year ago they are worth just £1900 right now, a horrendous drop in value.

I really think tomorrow’s results are the most significant in EVG/TCF’s history, money has simply got to start streaming in to bankroll the company, there can be no further share placings at these levels otherwise the shares will be diluted so much that it will be impossible for existing shareholders to ever get their money back.

Not my buys this morning, somebody else has had a good go though